NasdaqGS:APP
NasdaqGS:APPSoftware

AppLovin (NasdaqGS:APP) Reports Robust Q1 Earnings Despite Price Dip Over Last Quarter

AppLovin (NasdaqGS:APP) reported robust Q1 earnings with sales growth and improved net income, yet it faced a 4% share price decline over the last quarter. The price move contrasts with the broader market's flat performance but can be partly attributed to the substantial goodwill impairment and the securities class action lawsuit filed against the company. Despite these challenges, the ongoing share repurchase program and strategic advancements like Chartboost’s new capabilities on the MAX...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients, which aligns with a 7% share price increase over the last month. This, along with new offerings for Zepbound and strategic collaborations, potentially supported the company's stock performance. While the broader market showed a flat trajectory, the company's developments likely added weight to...